Louis Fehrenbacher

ORCID: 0000-0002-1300-1905

Also affiliated with Northern California Research

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer”.

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

New England Journal of Medicine(2004)10.1056/nejmoa032691

N/A

1.4DataRank · unranked

10954 citations

Louis Fehrenbacher, William Novotny, Thomas Cartwright, John Hainsworth, William Heim +18 more

Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

Breast Cancer Research and Treatment(2022)10.1007/s10549-021-06417-y

N/A

0.593DataRank · unranked

10 citations

Hanna Bandos, Priya Rastogi, Samuel A. Jacobs, André Robidoux, Louis Fehrenbacher +13 more

Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa160

N/A

0.330DataRank · unranked

8 citations

Daniel J. Schaid, Anthony Batzler, Reena S. Cecchini, Ann H. Partridge, Aaron D. Norman +9 more

Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad078

N/A

0DataRank · unranked

20 citations

Hanna Bandos, Priya Rastogi, Barry C. Lembersky, Jong‐Hyeon Jeong, Charles E. Geyer +11 more

Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.502

N/A

0DataRank · unranked

16 citations

Hanna Bandos, Peter C. Lucas, L. J. van ‘t Veer, Jia-Perng Jennifer Wei, Charles E. Geyer +15 more

Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.501

N/A

0DataRank · unranked

22 citations

Hanna Bandos, Priya Rastogi, Yi Zhang, Kai Treuner, Peter C. Lucas +14 more

Definitive Results of a Phase III Adjuvant Trial Comparing Six Cycles of FEC-100 to Four Cycles of AC in Women with Operable Node-negative Breast Cancer: The NSABP B-36 Trial (NRG Oncology)

Research Square(2021)10.21203/rs.3.rs-841103/v1

N/A

0DataRank · unranked

3 citations

Hanna Bandos, Priya Rastogi, Samuel A. Jacobs, André Robidoux, Louis Fehrenbacher +13 more